A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-Positive (SSTR+), Neuroendocrine Tumours of GastroEnteric or Pancreatic Origin
The purpose of this phase III trial is to evaluate the safety and efficacy of Peptide Receptor Radionuclide Therapy (PRRT) with 177- Lu-Edotreotide compared to standard of care therapies Everolimus, FOLFOX, and CAPTEM in patients with somatostatin receptor-positive (SSTR+) neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET).
Study ID: DP-1111-02CT
Trial Phase: Phase III
Trial Sponsor: ITM Solucin GmbH
Therapies Used in This Trial: Fluorouracil, Oxaliplatin, Capecitabine, Everolimus, Temozolomide, Leucovorin, FOLFOX, Peptide Receptor Radionuclide Therapy (PRRT), 177Lu-Edotreotide